MiniMed Group Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio...
Latest News
17 days ago · prnewswire.com
MiniMed Announces Board of Directors for its Next Chapter as an Independent Company/PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the composition of its Board of Directors following the
28 days ago · prnewswire.com
Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetesSix-month randomized trial found 8.1 percentage points more Time in Range and 0.6 percentage points lower HbA1c among higher responders. NORTHRIDGE, Calif.
2 months ago · fool.com
Why MiniMed Stock Was Soaring This WeekA new product introduction helped lift the top line. It seems there's more where that came from, with new product introductions scheduled over the coming months.
2 months ago · benzinga.com
These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales ResultsMiniMed Group Inc (NASDAQ:MMED) on Tuesday reported better-than-expected first-quarter sales results.
2 months ago · seekingalpha.com
MiniMed Group, Inc. (MMED) Q1 2027 Earnings Call TranscriptMiniMed Group, Inc. (MMED) Q1 2027 Earnings Call Transcript
2 months ago · marketbeat.com
MiniMed Group Q1 Earnings Call HighlightsMiniMed Group NASDAQ: MMED reported fiscal 2027 first-quarter revenue of $843 million, with organic revenue growth of 15.8%, as demand for its newer insulin-delivery and continuous glucose monitoring products supported growth in the United States and international markets.
2 months ago · prnewswire.com
MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth AccelerationStrong start to fiscal year with net sales of $843 million growing 17% as reported and 16% organic U.S. net sales growth accelerated to 13%; continued robust international net sales growth of 18% as reported, 17% organic Advanced global pipeline ahead of schedule with FDA submission for MiniMed Fit™, CE Mark for MiniMed Flex™, Vivera™ FCL U.S. pivotal trial enrollment completion, and IDE approval for next-gen extended wear MiniMed sensor Raises fiscal year 2027 organic revenue growth guidance NORTHRIDGE, Calif., Sept. 1, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today reported financial results for its first quarter (Q1) of fiscal year 2027 (FY27), ended July 31, 2026.
2 months ago · benzinga.com
Top Wall Street Forecasters Revamp MiniMed Group Expectations Ahead Of Q1 EarningsMiniMed Group, Inc. (NASDAQ:MMED) will release its first quarter earnings report before the opening bell on Tuesday, Sept. 1.
2 months ago · prnewswire.com
MiniMed to Participate in Upcoming Investor ConferencesNORTHRIDGE, Calif., Aug. 25, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that management will participate in fireside chats at the following investor conferences: 21st Annual Wells Fargo Healthcare Conference Tuesday, September 8, 2026, at 3:00 p.m.
3 months ago · prnewswire.com
MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest SensorMiniMed Flex™ with Instinct, made by Abbott, combines discreet design, up to 15 days of sensor wear and proven automation to reduce the work and interruptions of diabetes management NORTHRIDGE, Calif., Aug. 17, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced that the MiniMed Flex™ system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MMED